Business Wire

CyberArk Named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management

11.9.2024 18:04:00 EEST | Business Wire | Press release

Share

CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is positioned as a Leader for the sixth consecutive time and is positioned furthest in Completeness of Vision, which evaluates vendors on offering (product) strategy, innovation and market understanding among other evaluation criteria.

With 93% of organizations suffering two or more identity-related breaches in the last 12 months, managing and securing identities has become a critical requirement. The CyberArk Identity Security Platform enables organizations to secure the entire spectrum of identities, including workforce, IT, developer and machine, supporting modern access use cases such as the need to enforce Zero Standing Privileges in public cloud environments. A core component of the platform is CyberArk’s privileged access management (PAM) capabilities, which allow customers to apply flexible privilege controls to help prevent malicious account, credential and secrets access throughout the entire enterprise infrastructure.

“We are incredibly proud to once again be named a Leader by Gartner. CyberArk delivers identity security programs for a multi-cloud world. We feel that our position as a Leader in this year’s report, for the sixth consecutive time, is a testament to our commitment to ongoing innovation and customer success,” said Matt Cohen, CEO, CyberArk. “Identity security is no longer just about human identities. As identities – especially machine identities - proliferate, driven by new hybrid and multi-cloud environments, an effective identity security strategy must secure them all with the right level of privilege controls. CyberArk’s advanced PAM, secrets management and endpoint privilege security capabilities are key to empowering our customers to secure every identity and defend against cyberattacks.”

CyberArk aims to deliver the industry’s most comprehensive identity security platform, including:

  • Outstanding Customer Experience: CyberArk is committed to a customer-first approach, ensuring that all identities are secured with the right level of privilege controls, while putting the customer at the center of all it does. Its unified, SaaS-based platform notably simplifies and improves the administrator and end user experience to reduce cost and complexity, helping organizations accelerate their migration to the cloud with consistent identity security controls in place.
  • PAM Programs for a Multi-Cloud World: The CyberArk Identity Security Platform provides best-in-class, end-to-end PAM capabilities. CyberArk centrally and natively secures both shared and federated privileged access for IT and cloud ops teams supporting digital initiatives. By applying intelligent privilege controls within native tooling, CyberArk helps PAM programs scale across all environments – from long-lived systems in on-premises data centers to elastic cloud workloads, public cloud services and SaaS apps.
  • Unified, Cross-Platform Innovation, Powered by AI: CyberArk recently introduced new capabilities for securing every identity, further extending PAM controls to all identity types, including workforce identities. Offerings now include support for secure standing access and zero standing privileges, with the ability to isolate and audit privileged sessions. In addition, CyberArk Endpoint Privilege Manager now offers strong end-to-end passwordless authentication when signing into endpoints and elevating application controls. CyberArk’s unified portal means that the end user experience is enhanced with one-click, native access to enterprise resources, while intelligent privilege controls protect the user. Earlier this year, CyberArk also announced CORA AI™, which will allow organizations to analyze anomalies and apply next-level identity threat detection and response actions, reducing reaction times from hours to minutes.
  • World-Leading Partner Support and Technology Ecosystem: CyberArk aims to make it easier for partners to develop deep identity security practices and measurably reduce cybersecurity risk for customers. CyberArk invests heavily in its Channel Partner Program, with the launch of a new self-service portal for partners – as well as the CyberArk MSP Console - and new certifications underscoring its commitment to value creation for both joint customers and partners. CyberArk’s global ecosystem brings together more than 1,300 system integrators, managed service providers, strategic outsourcers, advisories, solution providers, distributors and marketplaces. Alongside this partner network, the CyberArk C3 technology alliance allows customers to make the most of their existing technology investments, featuring more than 200 certified integrations from providers of enterprise software, infrastructure and security solutions.

To download a complimentary copy of the 2024 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2024-mq-pam

1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Abhyuday Data, Michael Kelley, Nayara Sangiorgio, Felix Gaehtgens, Paul Mezzera, 9 September 2024

Gartner Disclaimers

GARTNER is a registered trademarks and service mark, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.

Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About CyberArk

CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, X, Facebook or YouTube.

Copyright © 2024 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240910351926/en/

Contacts

Investor Relations:
Srinivas Anantha, CFA
CyberArk
617-558-2132
ir@cyberark.com

Media:
Nick Bowman
CyberArk
+44 (0) 7841 673378
press@cyberark.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye